Aurobindo Pharma acquires Apotex's businesses in 5 European countries

Aurobindo Pharma had inked a binding agreement on July 14, 2018, to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certainly established trademarks, marketing authorisations and dossier licence rights in Poland.

New Delhi: Aurobindo Pharma on Monday said it has completed the Euro 74-million deal to acquire Apotex's commercial operations and certain supporting infrastructure in five European countries.

The company had inked a binding agreement on July 14, 2018, to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certainly established trademarks, marketing authorisations and dossier licence rights in Poland, the Czech Republic, the Netherlands, Spain and Belgium, Aurobindo Pharma said in a regulatory filing.

Read Also: Aurobindo Pharma Q3 profit rises 19.69 percent to Rs 712 crore on robust sales

This announcement does not constitute a recommendation to shareholders or potential investors, it added.

Aurobindo Pharma is headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic/product areas: antibiotics, antiretrovirals, cardiovascular products, central nervous system products, gastroenterological, and anti-allergic. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.